NMDA antagonist

NMDA antagonist

Neurology Any of a number of agents that protect against brain damage in neurologic disorders–eg, stroke; PCP–phencyclidine and ketamine are effective, but have psychotomimetic effects or damage neurons in the cerebral cortex; diazepam and barbiturates act at the GABA receptor channel complex, and may prevent the unwanted side effects of NMDA antagonists
References in periodicals archive ?
LevoCap ER is a once-a-day extended release formulation of levorphanol, a potent opioid which is also an SNRI and NMDA antagonist.
Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind omparison to alfentanil and placebo.
We demonstrated that central delivery of the NMDA antagonist MK-801 disrupted the acquisition of preferences for a grape flavor paired with a carbohydrate (polycose) in hungry rats.
But, until we have another FDA-approved NMDA antagonist to use, there are surely many people "living with the black dog" who would gladly risk a bad trip to cut the dog's leash.
In hippocampal slice cultures, nPM increased the neurotoxicity of N-methyl-D-aspartic acid (NMDA), a gluta-matergic agonist, which was in turn was blocked by the NMDA antagonist (2R)-amino-5-phosphonopentanoate (AP5).
Evidence about the effectiveness of the NMDA antagonist ketamine to reduce postoperative hyperalgesia and acute and long-lasting pain is inconclusive (5,6).
POSSIBLE DRUG DRUG NAME INTERACTIONS Namenda[R] (memantine) Other NMDA antagonist medications, Blocks the toxic effects including amantadine, an antiviral used to associated with excess treat the flu, dextromethorphan, prescribed glutamate and regulates to relieve coughs due to colds or flu, and glutamate activation.
The NIMH is sponsoring a randomized, double-blind trial of antidepressant therapy comparing placebo with the NMDA antagonist memantine, which is approved for the treatment of dementia.
Magnesium is an inexpensive and commonly used compound thought to be an NMDA antagonist (Charlton, 1998; Warlow et al.
This first-in-class drug candidate is believed to help regulate excitatory neurotransmission in two ways: through pre-synaptic inhibition of glutamate release via sigma-1 receptor agonist activity and through postsynaptic glutamate response modulation via uncompetitive, low-affinity NMDA antagonist activity.
Biohaven founders were among the first researchers at Yale University to discover the therapeutic potential of the NMDA antagonist ketamine and other glutamate modulating agents in the treatment of neuropsychiatric disorders.
The present study examined the effect of the NMDA antagonist drug MK-801 delivered directly into the Central Nervous System (CNS) on the acquisition and expression of conditioned flavor preferences in rats.